Innate Pharma

Innate Pharma, S.a.

Bristol-myers Squibb Compnay

Innate Pharma S.a.s.

University of Genoa

Novo Nordisk A/s

Novo Nordisk-a/s Novo Alle

University of Genova

Universita Di Genova

Pascale Andre

Mathieu Blery

Alessandro Moretta

Carine Paturel

Nicolai Wagtmann

Francois Romagne

Peter Andreas Nicolai Reumert Wagtmann

Mariella Della Chiesa

Caroline Soulas

Laurent Gauthier

Ashok Kumar Gupta

Kristian Kjaergaard

Stefan Zahn

Anders Svensson

Ivan Svendsen

Robert F Graziano

Jon Marc Wigginton

Soren Berg Padkjaer

Michael Wilken

Emanuela Marcenaro

Su Young Kim

Matthias Thorolfsson

Peter Andreas Wagtmann

Søren Berg Padkær

Cecile Bonnafous

François Romagne

Pieter Spee

Jérôme Tiollier

Michael Darron Robbins

Francois Romagné

Soeren Berg Padkaer

Pieter Johannes Louis Spee

Søren Berg Padkjær

Laurant Gauthier

Petrus Johannes Loius Spee

Milchael Wilken

Matthias Thórólfsson

Renaud Buffet

Nicolaï Wagtmann

Marcel Rozencweig

Caroline Denis

Luisa M Salter-Cid

Soren Berg Padkaer

Soeren Berg Padkjaer

Søren Berg Padkaer

The present invention relates to methods for the treatment of disease, notably cancer, using antibodies that specifically bind and inhibit human NKG2A. Included are therapeutic regimens that provide improved efficacy of anti-NKG2A antibodies.

Treatment regimens using anti-NKG2A antibodies

The present invention relates to methods for the treatment, prevention and diagnostic of diseases using compounds that specifically bind and inhibit human NKG2A in combination with compounds that bind and inhibit human PD-1. The invention also relates to assays to identify NKG2A+PD1+ tumor infiltrating NK and/or CD8 T cells.

Neutralization of inhibitory pathways in lymphocytes

The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.

Treatment of cancers using anti-NKG2A agents

This invention relates to the use of NKG2A-neutralizing agents to treat cancers that are poorly responsive to PD-1 neutralizing agents, as well as to the combined use of NKG2A-neutralizing agents and PD-1 neutralizing agents for the treatment of cancer.

Provided are methods for clinical treatment of cancer (e.g., solid tumors or hematological malignancies) using an anti-KIR antibody in combination with an anti-CTLA-4 antibody.

Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

Provided are methods for clinical treatment of multiple myeloma using an anti-KIR antibody in combination with an anti-CS 1 antibody.

Combination of anti-KIR and anti-CS1 antibodies to treat multiple myeloma

The present invention relates to methods of treating immune disorders, particularly autoimmune or inflammatory disorders, and methods of producing antibodies and other compounds for use in therapeutic strategies for treating such disorders. Generally, the present methods involve the use of antibodies or other compounds that prevent the stimulation of NKG2A receptors on NK cells, leading to the lysis of dendritic cells that contribute to the pathology of the disorders.

Monoclonal antibodies against NKG2A

Compositions comprising compounds that neutralize NK cell inhibitory receptors and methods of using such compositions in the treatment of hematological malignancies are provided.

Methods for treatment of recurrent hematological malignancies

This invention relates to compounds that inhibit KIR2DL1, 2 and/or 3 polypeptide comprising compounds (e.g., anti-KIR2DL1, 2, and/or 3 antibodies) that neutralize NK cell inhibitory receptors and methods of using such compounds and compositions containing in the treatment and prevention of inflammatory or autoimmune disorders.

Anti-KIR antibodies for the treatment of inflammatory and autoimmune disorders

Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.

Human anti-KIR antibodies

Growing community of inventors

Marseilles, France

Pascale Andre